RxDoctor Payments Data

Nima Rabbani

Nephrology · Encino, CANPI 1619179454

Payments from drug & device makers

$822in general payments, 2019–2025

Across 38 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$174
  • Amgen$158
  • Novo Nordisk$94
  • CMP Pharma, Inc.$52
  • AbbVie$48
  • DJO, LLC$46
  • plus $249 from 11 others

What the payments were for

  • Food & beverage$822100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$822 in reported general payments places this provider in the 40th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$1,099,204
Medicare patients
1,432
Services billed
11,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$113,845
TradjentaLinagliptin132$59,728
EliquisApixaban118$42,580
FarxigaDapagliflozin Propanediol70$34,633
JardianceEmpagliflozin46$27,967
VascepaIcosapent Ethyl95$25,673
RybelsusSemaglutide26$24,689
KerendiaFinerenone26$19,147
Sevelamer Carbonate26$16,176
TrulicityDulaglutide17$15,815
MounjaroTirzepatide12$14,289
ClinolipidFat Emulsion/Olive/Soy/Phospho48$13,587
ProcritEpoetin Alfa21$13,548
JanuviaSitagliptin Phosphate38$12,658
RetacritEpoetin Alfa-Epbx21$9,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$94$138,534131 claims
AstraZenecaFarxiga, Lokelma$21$41,25484 claims
BayerKerendia$174$19,14726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,341 nephrology providers in California.

Other nephrology in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →